Fibroblast growth factor-2

Drug Profile

Fibroblast growth factor-2

Alternative Names: Recombinant fibroblast growth factor-2; rFGF-2

Latest Information Update: 23 Jul 2010

Price : $50

At a glance

  • Originator Novartis
  • Class Fibroblast growth factors
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Cardiovascular disorders; Peripheral arterial occlusive disorders

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 17 Jul 2002 This agent is still in active development
  • 14 Feb 2001 Two studies have been added to the Ischaemic Heart Disease pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top